Preclinical evaluation and molecular docking of 1,3-benzodioxole propargyl ether derivatives as novel inhibitor for combating the histone deacetylase enzyme in cancer
Source abstract
Abstract
Even after huge strides in medicine, cancer continues to be a formidable disease, which is slated to become the leading cause of death worldwide. The present study investigates the 1,3-benzodioxole and its propargyl ether derivatives as a novel histone deacetylase enzyme inhibitor in order to cure cancer, as aberrant expression of histone deacetylases (HDACs) is associated with carcinogenesis. Bioinformatics approaches were employed to carry out preclinical and pharmacological evaluations of designed benzodioxole derivatives. Furthermore, their interaction with HDAC-1 enzyme was studied through computational methods for their specific inhibitory effects and evaluated for their LD50 (oral rat acute toxicity) value. In addition to this work, three-dimensional (3D) structure of HDAC-1 enzyme was extracted and evaluated using various parameters including Ramachandran plot and molecular docking stimulation. In our study, we found that compound 7 and compound 9 have higher binding score than approved drugs (SAHA, TSA and VPA). Importantly, these compounds were found to possess good pharmacological and pharmacokinetic properties and can be considered as potent novel compound to combat the HDAC-1 enzyme to cure cancer. Compounds were also analyzed and validated with parameters like absorption, metabolism, excretion, toxicity and synthetic accessibility during the preclinical evaluation. This study paves way to search for novel and potent small chemical compounds for inhibiting HDAC-1 enzyme and in particular to combat the cancer progression by interrupting the cell cycle.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Histone Deacetylase Inhibitors Research · Cholinesterase and Neurodegenerative Diseases · Protein Degradation and Inhibitors
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, Drug Discovery and Development Laboratory, University of Delhi, Delhi, India;
Department of Biotechnology, Stem Cell Research Laboratory, Delhi Technological University, Delhi, India;
Dr. B. R. Ambedkar Centre for Biomedical Research, University of Delhi, Delhi, India
Funding
Council of Scientific and Industrial Research
References (58)
Show source-provided references
1. 2017
2. A report, Over 17 lakh new cancer cases in India by 2020: ICMR; 2016. Available from: http://icmr.nic.in/icmrsql/archive/2016/7.pdf
3. 10.1016/S0092-8674(00)81683-910.1016/S0092-8674(00)81683-9 ↗
4. 10.1038/nrd213310.1038/nrd2133 ↗
5. 10.1038/icb.2011.10010.1038/icb.2011.100 ↗
6. 10.1038/3510607910.1038/35106079 ↗
7. 10.1016/S0959-437X(99)80027-610.1016/S0959-437X(99)80027-6 ↗
8. 10.5772/2745610.5772/27456 ↗
9. Singh VK · J Stem Cells · 2015 · 10 · 43
10. 10.1042/bj2002132110.1042/bj20021321 ↗
11. 10.1016/j.jmb.2004.02.00610.1016/j.jmb.2004.02.006 ↗
12. 10.1038/nrc177910.1038/nrc1779 ↗
13. 10.1093/nar/30.1.3810.1093/nar/30.1.38 ↗
14. 10.1038/nsmb.189910.1038/nsmb.1899 ↗
15. 10.1016/j.molcel.2013.05.02010.1016/j.molcel.2013.05.020 ↗
16. 10.1016/j.phrs.2010.02.01010.1016/j.phrs.2010.02.010 ↗
17. 10.1002/pros.2002210.1002/pros.20022 ↗
18. 10.1111/j.1349-7006.2001.tb02153.x10.1111/j.1349-7006.2001.tb02153.x ↗
19. 10.1007/s10549-005-6001-110.1007/s10549-005-6001-1 ↗
20. 10.1074/jbc.M51002320010.1074/jbc.M510023200 ↗
21. 10.1111/j.1600-0463.2005.apm_04.x10.1111/j.1600-0463.2005.apm_04.x ↗
22. 10.1038/sj.cdd.440156710.1038/sj.cdd.4401567 ↗
23. 10.1016/S1535-6108(04)00114-X10.1016/S1535-6108(04)00114-X ↗
24. 10.1677/erc.1.0124910.1677/erc.1.01249 ↗
25. 10.1073/pnas.071041310510.1073/pnas.0710413105 ↗
26. 10.1146/annurev-pharmtox-010611-13471210.1146/annurev-pharmtox-010611-134712 ↗
27. 10.1007/s12035-009-8067-y10.1007/s12035-009-8067-y ↗
28. 10.1016/j.ejmech.2012.03.05810.1016/j.ejmech.2012.03.058 ↗
29. 10.1158/0008-5472.CAN-06-004910.1158/0008-5472.CAN-06-0049 ↗
30. 10.1002/med.2002410.1002/med.20024 ↗
31. 10.7164/antibiotics.53.119110.7164/antibiotics.53.1191 ↗
32. 10.1016/j.compbiomed.2012.04.00110.1016/j.compbiomed.2012.04.001 ↗
33. 10.1634/theoncologist.12-10-124710.1634/theoncologist.12-10-1247 ↗
34. 10.1186/1756-8722-3-510.1186/1756-8722-3-5 ↗
35. 10.1158/1535-7163.MCT-07-202610.1158/1535-7163.MCT-07-2026 ↗
36. 10.1007/s00044-011-9623-310.1007/s00044-011-9623-3 ↗
37. 10.1002/(SICI)1098-1128(199603)16:2<207::AID-MED4>3.0.CO;2-410.1002/(SICI)1098-1128(199603)16:2<207::AID-MED4>3.0.CO;2-4 ↗
38. Batra JK · Mol Pharmacol · 1985 · 27 · 9410.1016/S0026-895X(25)11458-2 ↗
39. 10.1021/jm00393a01210.1021/jm00393a012 ↗
40. Yokota S · Cancer Res · 2000 · 60 · 2942
41. 10.1016/S0960-894X(00)00072-X10.1016/S0960-894X(00)00072-X ↗
42. Chimirri A · Pharmaco · 1996 · 51 · 125
43. 10.1016/S0223-5234(00)01195-810.1016/S0223-5234(00)01195-8 ↗
44. 10.1016/S0014-827X(02)01276-410.1016/S0014-827X(02)01276-4 ↗
45. 10.2174/15680260878678662410.2174/156802608786786624 ↗
46. 10.1016/j.drudis.2011.10.02310.1016/j.drudis.2011.10.023 ↗
47. 10.1038/nrd103210.1038/nrd1032 ↗
48. 10.1002/prot.1028610.1002/prot.10286 ↗
49. 10.1002/pro.556002091610.1002/pro.5560020916 ↗
50. 10.1038/356083a010.1038/356083a0 ↗
51. 10.1093/nar/gkm29010.1093/nar/gkm290 ↗
52. Trott O · J Comp Chem · 2010 · 3 · 45510.1002/jcc.21334 ↗
53. 10.1002/prot.2443310.1002/prot.24433 ↗
54. 10.1371/journal.pcbi.100238010.1371/journal.pcbi.1002380 ↗
55. 10.1002/0470037237.ch1610.1002/0470037237.ch16 ↗
56. 10.1016/0092-8674(94)90212-710.1016/0092-8674(94)90212-7 ↗
57. 10.1097/00007691-199810000-0002410.1097/00007691-199810000-00024 ↗
58. 10.1038/srep4271710.1038/srep42717 ↗